Our country has achieved the first mass production of medical-grade alpha isotopes at the Curie level.

MetaMuskRat · 2026-03-28T11:16:52+00:00

The China Spallation Neutron Source has achieved the first large-scale production of medical-grade alpha isotopes at the Curie level, which will promote the clinical application of alpha nuclear drugs, especially targeted therapy for advanced and late-stage tumors. This development addresses the previous reliance on imports and supports the growth of China's alpha nuclear drug industry.

MetaMuskRat

2026-03-28 11:16:52

Abstract generation in progress

On March 28, People’s Financial News reported that the Chinese Academy of Sciences Institute of High Energy Physics announced that the large-scale scientific facility China Spallation Neutron Source has recently achieved the first medical-grade curie-level mass production of alpha isotopes, which will accelerate the transition of China’s自主化 alpha nuclear medicine from laboratory to clinical application. Alpha isotopes, with their unique advantage of “high energy and short range,” can precisely kill cancer cells while causing minimal damage to surrounding healthy tissues, making them a powerful tool for tumor treatment, especially for targeted therapy in mid to late-stage tumors. However, for a long time, core therapeutic alpha isotopes such as actinium-225 and radium-223 have been entirely dependent on imports, and their supply is scarce. The mass production of these isotopes has become a globally recognized industry challenge due to multiple technical barriers, which has also restricted the development of China’s alpha nuclear medicine industry. (CCTV News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.